loading page

SARS-CoV-2 and the safety margins of cell-based biological medicinal products
  • +3
  • Jens Modrof,
  • Astrid Kerschbaum,
  • Maria Farcet,
  • Daniela Niemeyer,
  • Victor Corman,
  • Thomas Kreil
Jens Modrof
Takeda Pharmaceutical Co Ltd
Author Profile
Astrid Kerschbaum
Baxter AG Austria
Author Profile
Maria Farcet
Baxter AG Austria
Author Profile
Daniela Niemeyer
Charité Universitätsmedizin Berlin
Author Profile
Victor Corman
Charité Universitätsmedizin Berlin
Author Profile
Thomas Kreil
Takeda Austria Vienna
Author Profile

Abstract

With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants was tested by routine adventitious virus testing of fermenter harvest.

Peer review status:Published

02 Jun 2020Submitted to Biotechnology and Bioengineering
03 Jun 2020Assigned to Editor
03 Jun 2020Submission Checks Completed
15 Jun 2020Review(s) Completed, Editorial Evaluation Pending
Aug 2020Published in Biologicals. 10.1016/j.biologicals.2020.08.010